Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.

Cancer - 1 Jan 2011

Vranic Semir, Teruya Bryan, Repertinger Susan, Ulmer Pamela, Hagenkord Jill, Gatalica Zoran

Abstract excerpt

BACKGROUND: The current study was performed to determine the impact of polysomy 17 on the interpretation of HER2 testing of invasive breast carcinomas using fluorescent in situ hybridization methods. Current American Society of Clinical Oncology/College of American Pathologists guidelines define HER2-positive tumors as those with >6 HER2 genes per nucleus or those with HER2/CEP17 (chromosome 17) ratio >2.2. These...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Aneuploidy
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 17

Share to DNA Copy Number Variations

Share to Genes, erbB-2

Share to In Situ Hybridization, Fluorescence

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 20803611
DOI: 10.1002/cncr.25580

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.PMID 20803611Read ↗

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Semantic proximity Read ↗

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 TestingSemantic proximity Read ↗

Effect of High Copy Number of HER2 Associated With Polysomy 17 on HER2 Protein Expression in Invasive Breast CarcinomaSemantic proximity Read ↗

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily PracticeSemantic proximity Read ↗

Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistrySemantic proximity Read ↗

The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the BreastSemantic proximity Read ↗

Her-2/neu overexpression due to polysomy 17 in breast cancer: molecular testing to guide therapeutic options.Semantic proximity Read ↗

Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancerSemantic proximity Read ↗

Polysomy 17 and HER-2 Amplification: True, True, and UnrelatedSemantic proximity Read ↗

HER2 Assessment by Immunohistochemical Analysis and Fluorescence In Situ HybridizationSemantic proximity Read ↗

Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort studySemantic proximity Read ↗

Determining True <i>HER2</i> Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-<i>HER2</i> Targeted TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.